首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Drug Utilization Evaluation of Piperacillin and Tazobactum at a Tertiary Care Center in Hyderabad, India.
【24h】

Drug Utilization Evaluation of Piperacillin and Tazobactum at a Tertiary Care Center in Hyderabad, India.

机译:印度海得拉巴三级护理中心的哌拉西林和他唑巴坦的药物利用评估。

获取原文
           

摘要

Drug use evaluation is an ongoing, systematic, criteria-based program of medicine evaluations that will help ensure appropriate medicine use. If therapy is determined to be inappropriate, interventions with providers or patients will be necessary to optimize pharmaceutical therapy. Empirical therapy forms the basis of treatment in India mostly and it is the responsibility of DTC (Drugs and therapeutics committee) to organize a DUE study and adopt suitable protocol for controlling irrational drug use. In our study we have developed a data collection form based upon WHO guidelines for conducting a DUE study on piperacillin and tazobactum use evaluation. To assess the usage of piperacillin and tazobactum at a tertiary care center Hyderabad compared to the indications for piperacillin and tazobactum use and standard treatment guidelines and provide recommendations to improve rational use of piperacillin and tazobactum at these hospitals and reduce the development of further antibiotic resistance, prevent ADRs associated with the drug, and to reduce the economic burden on the patient with inappropriate use. For conducting the evaluation process we had followed the standard guide lines formulated by WHO. The gender distributions of casesheets were male- 42, female- 23. Indication wise the distribution of case sheets were mostly treated for surgical prophylaxis, prophylaxis and infections. Out of 65 cases 65 (99%) has met the established criteria, they are as per STGs. Illness most frequently treated with piperacillin and tazobactum is ckd with acute deterioration (29.23%). The minimum number of days of treatment was 3 day and the maximum number of days of treatment was 14days. All patient folders evaluated with regards to HD, SEPTIC SHOCK, PNEMOMEDIATINM etc were found to meet the standard criteria appropriate for piperacillin and tazobactum use with respect to dose, and dose frequency. However, in the case of dose duration the evaluation was found to be largely inappropriate for all the justified indications.
机译:药物使用评估是一项持续,系统,基于标准的药物评估计划,有助于确保适当的药物使用。如果确定治疗不合适,则必须对提供者或患者进行干预以优化药物治疗。在印度,经验疗法主要是治疗的基础,DTC(药品和治疗委员会)的职责是组织DUE研究并采用适当的方案来控制不合理的药物使用。在我们的研究中,我们根据WHO指南开发了一种数据收集表,用于进行关于哌拉西林和他唑巴坦使用评估的DUE研究。为了评估海德拉巴三级医疗中心的哌拉西林和他唑巴坦的使用情况,并与哌拉西林和他唑巴坦的适应症及标准治疗指南进行比较,并提供建议,以改善这些医院对哌拉西林和他唑巴坦的合理使用,并减少进一步的抗生素耐药性的产生,防止与药物相关的ADR,并减少不当使用对患者的经济负担。为了进行评估,我们遵循了世界卫生组织制定的标准指南。病例表的性别分布是男性-42,女性-23。明智的做法是,病例表的分布主要用于手术预防,预防和感染。在65个案例中,有65个(99%)符合既定标准,符合STG的规定。用哌拉西林和他唑巴坦治疗最常见的疾病是ckd,急剧恶化(29.23%)。最小治疗天数为3天,最大治疗天数为14天。发现所有就HD,SEPTIC SHOCK,PNEMOMEDIATINM等进行评估的患者资料夹均符合适用于哌拉西林和他唑巴坦的剂量和给药频率的标准标准。但是,在服药期间,对于所有合理的适应症,评估均被认为是不合适的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号